Abstract:Background: Chronic myeloid leukemia (CML) is a malignant hyperplastic tumor of the bone marrow originating from pluripotent hematopoietic stem cells. The advent of tyrosine kinase inhibitors (TKIs) has greatly improved the survival rate of patients with CML. However, TKI-resistance leads to the disease recurrence and progression. This study aimed to identify immune-related genes (IRGs) associated with CML progression. Methods: We extracted the gene's expression profiles from the Gene Expression Omnibus (GEO). Bioinformatics analysis was used to determine the differentially expressed IRGs of CML and normal peripheral blood mononuclear cells (PBMCs). Functional enrichment and gene set enrichment analysis (GSEA) were used to explore its potential mechanism. Hub genes were identified using Molecular Complex Detection (MCODE) and the CytoHubba plugin. The hub genes' diagnostic value was evaluated using the receiver operating characteristic (ROC). The relative proportions of infiltrating immune cells in each CML sample were evaluated using CIBERSORT. Quantitative real-time PCR (RT-qPCR) was used to validate the hub gene expression in clinical samples. Results: A total of 31 differentially expressed IRGs were identified. GO analyses revealed that the modules were typically enriched in the receptor ligand activity, cytokine activity, and endopeptidase activity. KEGG enrichment analysis of IRGs revealed that CML involved Th17 cell differentiation, the NF-kappa B signaling pathway, and cytokine-cytokine receptor interaction. A total of 10 hub genes were selected using the PPI network. GSEA showed that these hub genes were related to the gamma-interferon immune response, inflammatory response, and allograft rejection. ROC curve analysis suggested that six hub genes may be potential biomarkers for CML diagnosis. Further analysis indicated that immune cells were associated with the pathogenesis of CML. The RT-qPCR results showed that proteinase 3 (PRTN3), cathepsin G (CTSG), matrix metalloproteinase 9 (MMP9), resistin (RETN), eosinophil derived neurotoxin (RNase2), eosinophil cationic protein (ECP, RNase3) were significantly elevated in CML patients' PBMCs compared with healthy controls. Conclusion: These results improved our understanding of the functional characteristics and immune-related molecular mechanisms involved in CML progression and provided potential diagnostic biomarkers and therapeutic targets.

Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

Proteomics-based Identification of Human Acute Leukemia Antigens That Induce Humoral Immune Response

Serological identification of immunogenic antigens in acute monocytic leukemia.

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma

Bioinformatics analysis and identification of hub genes and immune-related molecular mechanisms in chronic myeloid leukemia

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

Prediction and Identification of HLA-A*0201-restricted Epitopes from Leukemia-Associated Protein MLAA-22 Which Elicit Cytotoxic T Lymphocytes

Proteomic Analysis of Human Acute Leukemia Cells

Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma.

Analysis of the Different Proteomes Between the Acute Leukemia Cells and Normal White Blood Cells

[Bioinformatic Analysis and Identification for a Novel Antigen MLAA-22 in Acute Monocytic Leukemia].

Bioinformatics and Raman spectroscopy-based identification of key pathways and genes enabling differentiation between acute myeloid leukemia and T cell acute lymphoblastic leukemia

Serum Peptidome Based Biomarkers Searching for Monitoring Minimal Residual Disease in Adult Acute Monocytic Leukemia

Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34

[Preliminarily Screening of Serum Characteristic Markers in Acute Myeloid Leukemia and Clinical Significance].

Analysis of Altered Proteins Related to Blast Crisis in Chronic Myeloid Leukemia by Proteomic Study.

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia